Urease Inhibitor

Flurofamide is an effective bacterial urease inhibitor and antibacterial agent. Flurofamide inhibits urease and partially inhibits the chemotactic activity of Helicobacter pylori strain CPY3401. Flurofamide inhibits the growth of Ureaplasma urealyticum. Flurofamide reduces blood ammonia. Flurofamide can be used in the research of infectious urinary stones.

N-Butylthiophosphoric triamide (NBPT) is a potent urease inhibitor. Butylthiophosphoric triamide inhibits nitrification and reduces the conversion of urea to NH3 gas.

Butylboronic acid is a competitive soybean urease inhibitor with an IC₅₀ of 2.9 mM and a K_i of 1.5 mM.

2,5-Dimethyl-1,4-benzoquinone is a jack bean urease (HY-P2767) inhibitor (IC₅₀: 0.98 μM). 2,5-Dimethyl-1,4-benzoquinone can be used in the study of soil urease activity in agriculture.

Urease-IN-3 (Compound L12) is a potent inhibitor of Urease with an IC₅₀ of 1.449 μM. Urease-IN-3 is a flavonoid analogue compound.

CCPD-Q (CCPD-Quinone) is a quinone derivative of phenylenediamine-based tire wear compounds, as well as a Urease inhibitor against Helicobacter pylori, with an IC₅₀ value of 41.50 μM. CCPD-Q can be used in studies related to Helicobacter pylori infection.

Urease-IN-25 (Compound 10a) is a urease inhibitor with an IC₅₀ value of 0.50 μM against jack bean urease. Urease-IN-25 can be used in the research of Helicobacter pylori infection, chronic gastritis, peptic ulcer disease, gastric cancer, mucosa-associated lymphoid tissue lymphoma, and other conditions.

Urease-IN-24 is a cryptococcal urease inhibitor with a IC₅₀ of 89.96 nM and a K_i of 64.3 nM. Urease-IN-24 acts as a competitive nickel-coordinating inhibitor that coordinates with the nickel center at the catalytic site of the enzyme via its carbonyl group. Urease-IN-24 reduces the capsule thickness of Cryptococcus neoformans and Cryptococcus gattii, increases cell membrane permeability, and inhibits melanin production. Urease-IN-24 exhibits fungicidal activity against Cryptococcus species. Urease-IN-24 can be used in the research of cryptococcosis.

Urease-IN-6 is a potent inhibitor of Urease with an IC₅₀ of 14.2 μM. Urease-IN-6 can be used in study peptic and gastric ulcers .

Antimicrobial agent-54 is a ciprofloxacin-derived multi-target antimicrobial agent that inhibits E. coli DNA gyrase, S. aureus topoisomerase IV, LpxC and urease with IC₅₀ values of 0.182, 3.501, 0.052 and 6.254 μM, respectively. The MIC of Antimicrobial agent-54 against E. coli ATCC 8739 is 0.20 μM. Antimicrobial agent-54 interferes with bacterial cell division, causes transient membrane disruption in Gram-positive bacteria, and induces aberrant penicillin-binding protein activity in Gram-negative bacteria. Antimicrobial agent-54 can be used in the research of bacterial infections, including multidrug-resistant bacterial infections and mycobacterial infections.

Urease-IN-2 (compound 8g) is a non-competitive urease inhibitor with an IC₅₀ of 0.94 μM and a K_i of 1.6 μM. Urease-IN-2 inhibits the Jack bean urease (JBU) in a non-competitive manner.

Urease-IN-23 is a cryptococcal urease inhibitor with antifungal activity. AF55 exhibits mixed-type inhibition against cryptococcal urease, binds to both the nickel ion site at the enzyme's catalytic center and the allosteric site, impairs urease catalytic efficiency, simultaneously disrupts fungal virulence structures and damages cell membrane integrity. The IC₅₀ and K_i values of Urease-IN-23 against cryptococcal urease are 54.92 nM and 149.1 nM, respectively. Urease-IN-23 significantly reduces the capsule thickness of Cryptococcus neoformans and Cryptococcus gattii, increases fungal cell membrane permeability, and completely blocks melanin synthesis. Urease-IN-23 shows no toxicity in the Galleria mellonella larval model. Urease-IN-23 can be used in studies related to fungal infections.

Urease-IN-14 (compound 15) is an urease inhibitor and antioxidant. Urease-IN-14 shows DPPH radical scavenging and urease inhibitory activities with IC₅₀ values 151.7 μM and 41.6 μM, respectively.

Urease-IN-21 (Compound 11b) is a Urease inhibitor with an IC₅₀ of 0.12  μM. Urease-IN-21 has potent antibacterial activity against helicobacter pylori (H. pylori) and inhibitor activity against P450 enzyme (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 can be used for H. pylori infection research.

Urease-IN-19 (Compound 3c) is a potent urease inhibitor with an IC₅₀ value of 2.7 µM. Urease-IN-19 is promising for research of kidney stones and stomach ulcers.

Urease/thymidine phosphorylase-IN-1 (compound 8) is a urease and thymidine phosphorylase inhibitor with a urease IC₅₀ of 8.20 μM, thymidine phosphorylase IC₅₀ of 9.29 μM. Urease/thymidine phosphorylase-IN-1 can be used for the research of helicobacter pylori infection, proteus mirabilis infection, cancer.

Urease-IN-16 (compound 4e) is a urease inhibitor, with an IC₅₀ value of 132 μmol/L. Urease-IN-16 can coordinate with the nickel atom through the oxygen atoms of carbonyl or boronic acid groups. Urease-IN-16 shows great potential as an additive in the development of efficient fertilizers and medical applications.

Urease-IN-22 (Compound 9L) is a Urease inhibitor with an IC₅₀ of 0.15  μM. Urease-IN-22 is a piperazine-based derivative of Benzimidazole (HY-Y1825).

Urease-IN-10 (Conjugate 4) is a competitive Urease inhibitor, with an IC₅₀ of 3.59±0.07 μM and a K_i of 7.45 μM. Urease-IN-10 is a conjugate consisting of Diclofenac (HY-15036) and Sulfanilamide (HY-B0242). Diclofenac-sulfanilamide inhibits the Jack bean urease(JBU) in a competitive manner.

N-Butylthiophosphoric triamide (Standard) (NBPT (Standard)) is the analytical standard of N-Butylthiophosphoric triamide (HY-107199). This product is intended for research and analytical applications. N-Butylthiophosphoric triamide (NBPT) is a potent urease inhibitor. Butylthiophosphoric triamide inhibits nitrification and reduces the conversion of urea to NH3 gas.